Literature DB >> 11342601

Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis.

C A Hunter1, D Yu, M Gee, C V Ngo, C Sevignani, M Goldschmidt, T V Golovkina, S Evans, W F Lee, A Thomas-Tikhonenko.   

Abstract

The ability of various infections to suppress neoplastic growth has been well documented. This phenomenon has been traditionally attributed to infection-induced concomitant, cell-mediated antitumor immunity. We found that infection with Toxoplasma gondii effectively blocked neoplastic growth of a nonimmunogenic B16.F10 melanoma. Moreover, this effect was independent of cytotoxic T or NK cells, production of NO by macrophages, or the function of the cytokines IL-12 and TNF-alpha. These findings suggested that antitumor cytotoxicity was not the primary mechanism of resistance. However, infection was accompanied by strong, systemic suppression of angiogenesis, both in a model system and inside the nascent tumor. This suppression resulted in severe hypoxia and avascular necrosis that are incompatible with progressive neoplastic growth. Our results identify the suppression of tumor neovascularization as a novel mechanism critical for infection-induced resistance to tumors.

Entities:  

Mesh:

Year:  2001        PMID: 11342601     DOI: 10.4049/jimmunol.166.10.5878

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

Review 1.  Microorganisms and cancer: quest for a therapy.

Authors:  A M Chakrabarty
Journal:  J Bacteriol       Date:  2003-05       Impact factor: 3.490

2.  Sepsis inhibits tumor growth in mice with cancer through Toll-like receptor 4-associated enhanced Natural Killer cell activity.

Authors:  Clara Vigneron; Adrien Mirouse; Hamid Merdji; Christophe Rousseau; Clément Cousin; Fanny Alby-Laurent; Jean-Paul Mira; Jean-Daniel Chiche; Jean-François Llitjos; Frédéric Pène
Journal:  Oncoimmunology       Date:  2019-07-19       Impact factor: 8.110

3.  Toxoplasma gondii in cancer patients receiving chemotherapy: seroprevalence and interferon gamma level.

Authors:  Mona Ibrahim Ali; Wegdan Mohamed Abd El Wahab; Doaa Ahmed Hamdy; Ahmed Hassan
Journal:  J Parasit Dis       Date:  2019-03-30

4.  The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors.

Authors:  Michael Dews; Jamie L Fox; Stacy Hultine; Prema Sundaram; Wenge Wang; Yingqiu Y Liu; Emma Furth; Gregory H Enders; Wafik El-Deiry; Janell M Schelter; Michele A Cleary; Andrei Thomas-Tikhonenko
Journal:  Cancer Res       Date:  2010-10-12       Impact factor: 12.701

5.  Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.

Authors:  Jason R Baird; Katelyn T Byrne; Patrick H Lizotte; Seiko Toraya-Brown; Uciane K Scarlett; Matthew P Alexander; Mee Rie Sheen; Barbara A Fox; David J Bzik; Marcus Bosenberg; David W Mullins; Mary Jo Turk; Steven Fiering
Journal:  J Immunol       Date:  2012-12-07       Impact factor: 5.422

6.  Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment.

Authors:  Jason R Baird; Barbara A Fox; Kiah L Sanders; Patrick H Lizotte; Juan R Cubillos-Ruiz; Uciane K Scarlett; Melanie R Rutkowski; Jose R Conejo-Garcia; Steven Fiering; David J Bzik
Journal:  Cancer Res       Date:  2013-05-23       Impact factor: 12.701

Review 7.  Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines.

Authors:  Barbara A Fox; Kiah L Sanders; Shan Chen; David J Bzik
Journal:  Trends Parasitol       Date:  2013-08-05

8.  Immunosurveillance by antiangiogenesis: tumor growth arrest by T cell-derived thrombospondin-1.

Authors:  Keri L Schadler; Erika J Crosby; Alice Yao Zhou; Dong Ha Bhang; Lior Braunstein; Kwan Hyuck Baek; Danielle Crawford; Alison Crawford; Jill Angelosanto; E John Wherry; Sandra Ryeom
Journal:  Cancer Res       Date:  2014-03-03       Impact factor: 12.701

9.  Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer.

Authors:  Tohru Yamada; Masatoshi Goto; Vasu Punj; Olga Zaborina; Mei Ling Chen; Kazuhide Kimbara; Dibyen Majumdar; Elizabeth Cunningham; Tapas K Das Gupta; Ananda M Chakrabarty
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-22       Impact factor: 11.205

10.  Inhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis.

Authors:  Ju Ock Kim; Sung Soo Jung; Sun Young Kim; Tae Yun Kim; Dae Whan Shin; Jae Ho Lee; Young Ha Lee
Journal:  J Korean Med Sci       Date:  2007-09       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.